Avecho Biotechnology Limited AI Stock Analysis
Want to see AU:AVE full AI Analyst Report?
Avecho Biotechnology Limited (AVE) AI Stock Analysis
Avecho Biotechnology Limited
(ASX:AVE)
The score is held back primarily by ongoing significant losses and equity erosion despite improved revenue growth and a 2025 shift to positive operating/free cash flow. Technicals are weak with the stock trading below key moving averages and a negative MACD, and valuation is constrained by a negative P/E with no dividend support.
Avecho Biotechnology Limited (AVE) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 38.64M
- Dividend Yield
- ―
- Average Volume (3M)
- 3.68M
- Price to Earnings (P/E)
- -8.0
- Beta (1Y)
- 1.72
- Revenue Growth
- -46.59%
- EPS Growth
- 9.09%
- Country
- Australia
- Employees
- 9
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Avecho Biotechnology Limited Business Overview & Revenue Model
Company Description
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operat...
Avecho Biotechnology Limited Financial Statement Overview
Summary
Revenue growth improved in 2025 (~12% vs. ~1% in 2024) and cash flow turned positive (operating and free cash flow ~A$1.1m). Balance sheet leverage is low, but persistent operating/net losses (e.g., ~A$4.4m net loss in 2025) and a declining equity base materially weaken overall financial quality.
Income Statement
28NegativeBalance Sheet
52NeutralCash Flow
57Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.02M | 1.24M | 1.13M | 473.55K | 1.13M | 793.60K |
| Gross Profit | 543.05K | 751.29K | 671.93K | -43.80K | 793.12K | 507.94K |
| EBITDA | -7.83M | -5.87M | -2.92M | -3.24M | -2.11M | -2.98M |
| Net Income | -3.66M | -4.42M | -3.12M | -3.44M | -2.34M | -3.42M |
Balance Sheet | ||||||
| Total Assets | 8.41M | 7.11M | 5.00M | 7.32M | 3.35M | 5.25M |
| Cash, Cash Equivalents and Short-Term Investments | 6.61M | 4.66M | 2.37M | 5.50M | 1.47M | 3.26M |
| Total Debt | 227.54K | 14.47K | 1.08M | 175.15K | 246.07K | 93.91K |
| Total Liabilities | 6.50M | 5.55M | 1.73M | 941.54K | 920.66K | 709.36K |
| Stockholders Equity | 1.91M | 1.56M | 3.27M | 6.38M | 2.42M | 4.54M |
Cash Flow | ||||||
| Free Cash Flow | -3.48M | 1.10M | -3.97M | -3.18M | -1.72M | -3.30M |
| Operating Cash Flow | -3.48M | 1.10M | -3.97M | -3.18M | -1.67M | -3.10M |
| Investing Cash Flow | -2,000 | 0 | -15.73K | 0 | -53.12K | -202.82K |
| Financing Cash Flow | 4.16M | 1.19M | 854.59K | 7.22M | -78.22K | 4.69M |
Avecho Biotechnology Limited Peers Comparison
Overall Rating
- AU:AVE48Neutral
AU:PAR47Neutral
AU:RCE46Neutral
AU:IMU39Underperform
AU:IMM38Underperform
AU:PTX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:AVE | 48Neutral | AUD 42.50M | -8.00 | -211.39% | ― | -46.59% | 9.09% |
| AU:PAR | 47Neutral | AUD 153.48M | -1.61 | -1189.87% | ― | 53.78% | -206.24% |
| AU:RCE | 46Neutral | AUD 105.52M | -6.95 | 84.67% | ― | ― | 42.51% |
| AU:IMU | 39Underperform | AUD 19.78M | -0.11 | -414.10% | ― | ― | -2.15% |
| AU:IMM | 38Underperform | AUD 35.38M | -0.46 | -98.86% | ― | ― | -27.73% |
| AU:PTX | 37Underperform | AUD 68.63M | -9.13 | -44.93% | ― | ― | 25.27% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:AVE | Avecho Biotechnology Limited | 0.01 | 0.00 | 20.00% | |
| AU:IMU | Imugene Ltd | 0.03 | -0.28 | -89.03% | |
| AU:PAR | Paradigm Biopharmaceuticals Ltd. | 0.24 | -0.12 | -32.88% | |
| AU:IMM | Immutep Ltd | 0.03 | -0.24 | -90.38% | |
| AU:PTX | Prescient Therapeutics Limited | 0.06 | 0.01 | 29.17% | |
| AU:RCE | Recce Pharmaceuticals Ltd. | 0.36 | -0.09 | -19.10% |
Avecho Biotechnology Limited Corporate Events
Avecho advances Phase III insomnia trial and expands global CBD patent and licensing strategy
Avecho has restarted recruitment and dosing for the final stage of its pivotal Phase III clinical trial of a TPM®-enhanced CBD soft-gel capsule for insomnia, aiming for 519 completed participants after a positive interim analysis and a clean safety p...
Avecho names new CFO as late-stage insomnia program advances
Avecho Biotechnology has appointed Subaraj Subramaniam as Chief Financial Officer, effective 27 October 2026, replacing Melanie Leydin after her seven-year tenure overseeing the company’s finance and governance functions. Subramaniam brings more than...
Avecho says no undisclosed news behind share price spike after ASX query
Avecho Biotechnology Limited has responded to an ASX price and volume query after its shares rose from A$0.014 to a high of A$0.019 and experienced unusually heavy trading. The company told the exchange it is not aware of any undisclosed information...
Avecho to Spotlight Phase III CBD Insomnia Trial at Canaccord Conference
Avecho Biotechnology will present at the Canaccord Drug and Device Conference in Noosa, where CEO Dr Paul Gavin is set to update investors on the company’s Phase III trial of its TPM-enhanced CBD soft-gel capsule for insomnia and outline planned acti...
Avecho Advances Phase III CBD Insomnia Trial Ahead of ASX SMIDcaps Presentation
Avecho Biotechnology Limited will present at the ASX SMIDcaps Conference, where CEO Dr Paul Gavin will update investors on the company’s Phase III trial of its CBD TPM soft-gel capsule for insomnia and outline planned activities over the next 12 to 1...
Avecho resumes final recruitment for pivotal Phase III insomnia trial
Avecho Biotechnology has restarted recruitment for the final stage of its pivotal Phase III clinical trial of a TPM-enhanced cannabidiol soft-gel capsule targeting insomnia in adults. The multi-centre, randomised, double-blind, placebo-controlled stu...
Avecho Issues 7.9 Million Unquoted Options Under Employee Incentive Scheme
Avecho Biotechnology Limited has notified the market of the issue of 7,923,243 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates. The move underscores the company’s continued use of equity-based compe...
Avecho hires senior dealmaker to drive CBD insomnia capsule partnerships
Avecho Biotechnology has appointed senior international biopharmaceutical executive Eve Williamson as a strategic business development consultant to bolster its global partnering and licensing efforts. Williamson, formerly Vice President and Global H...
Avecho Biotechnology Cuts Shareholder Numbers via Small Holding Sale Facility
Avecho Biotechnology Limited has completed a small holding share sale facility aimed at helping shareholders with low-value holdings exit their positions without brokerage or handling fees. The offer targeted investors whose shares were valued at und...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026